At a glance
ClinicalIndex Comparison Record- ✓Home diastolic BP >85 mmHg and home systolic BP <180 mmHg
- ✓Clinic diastolic BP 90-110 mmHg and clinic systolic BP <180 mmHg (seated, >5 minutes)
- ✕Secondary forms of hypertension
- ✕Currently on three or more antihypertensive drugs
- ✕Isolated systolic hypertension
- ✕Known cardiovascular disease including angina, heart failure, pacemaker, MI, revascularization, stroke, or TIA
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)
In Brief
A Phase 4 clinical trial evaluating Hydrochlorothiazide and Atenolol for Hypertension. Completed, enrolled 1,701 participants across 3 sites.
Detailed Summary
There are many medications available for the treatment of high blood pressure (hypertension), but finding the right one for a specific patient can be challenging. In fact, it is estimated that only 34% of people with hypertension have their blood pressure under control. The hypothesis is that genetic differences between individuals influence their response to antihypertensive medications. This study is aimed at determining the genetic factors that may influence a person's response to either a beta-blocker or a thiazide diuretic. The hope is that through this research, we may someday be able to use an individual's genetic information to guide the selection of their blood pressure medicine, leading to better control of blood pressure, and less need for the current trial and error process.
Study Details
Timeline
Interventions
atenolol 50 or 100 mg hydrochlorothiazide 12.5 or 25 mg
atenolol 50 mg, then 100 mg if BP \< 120/70, then add HCTZ 12.5 mg if BP \< 120/70, then HCTZ 25 mg if BP \< 120/70